| [1] |
Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis [J]. Arthritis Res Ther, 2011, 13(6): 250.
|
| [2] |
Yu C, Li P, Dang X, et al. Lupus nephritis: new progress in diagnosis and treatment [J]. J Autoimmun, 2022, 132: 102871.
|
| [3] |
Mahajan A, Amelio J, Gairy K, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression [J]. Lupus, 2020, 29(9): 1011-1020.
|
| [4] |
Krustev E, Clarke AE, Barber MRW. B cell depletion and inhibition in systemic lupus erythematosus [J]. Expert Rev Clin Immunol, 2023, 19(1): 55-70.
|
| [5] |
Shi F, Xue R, Zhou X, et al. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease [J]. Immunopharmacol Immunotoxicol, 2021, 43(6): 666-673.
|
| [6] |
Chen L, Teng Y, Ma Q, et al. Efficacy and safety of telitacicept in patients with class III-V lupus nephritis: a real-world retrospective cohort study [J]. Int Immunopharmacol, 2025, 154: 114596.
|
| [7] |
Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis [J]. N Engl J Med, 2020, 383(12): 1117-1128.
|
| [8] |
Gatto M, Saccon F, Andreoli L, et al. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN): results from a large, nationwide, multicentric cohort [J]. J Autoimmun, 2021, 124: 102729.
|
| [9] |
Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [J]. Arthritis Care Res (Hoboken), 2025, 77(9): 1045-1065.
|